LYVISPAH

Peak

baclofen

NDAORALGRANULES
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9

Mechanism of Action

GABA A Agonists

Pharmacologic Class:

gamma-Aminobutyric Acid-ergic Agonist

Clinical Trials (5)

NCT03058237Phase 1Completed

A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers

Started Jan 2017
40 enrolled
Healthy Volunteers
NCT02511886Phase 2Completed

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Started Sep 2015
18 enrolled
Alcohol Use Disorder
NCT01051128Phase 3Withdrawn

Continuous Intrathecal Baclofen Infusion for Chronic Spasticity

Started Jan 2010
0
Spasticity
NCT00802035Phase 1Completed

ALK29-002: A Study of Baclofen Formulations in Healthy Adults

Started Nov 2008
16 enrolled
Alcohol Dependence
NCT00516503Phase 3Completed

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

Started Feb 2008
208 enrolled
Chronic Myeloproliferative DisordersLeukemiaLymphoma+7 more

Loss of Exclusivity

LOE Date
Sep 29, 2041
189 months away
Patent Expiry
Sep 29, 2041

Patent Records (5)

Patent #ExpiryTypeUse Code
10792262
Jul 29, 2039
Product
U-3263
11654124
Jul 29, 2039
Product
11931328
Jul 29, 2039
Product
11491125
Sep 29, 2041
Product
U-3488
11850225
Sep 29, 2041
Product
U-3488